FindTrial
Sign In

pre-dispensed

DRUG4 trials

Sponsors

Hospices Civils De Lyon, Novartis Pharma AG, Fundacio Privada Mon Clinic Barcelona, Hospital General Universitario Gregorio Maranon

Conditions

AsthmaChronic Obstructive Pulmonary DiseaseChronic obstructive pulmonary diseases with Heart Failure with eyection ventricular ejection fraction between 35-50%

Phase 3

A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.
Not yet recruitingCTIS2022-502365-26-00
Novartis Pharma AGAsthma
Target: 22Updated: 2026-06-02

Phase 4

Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE
CompletedCTIS2022-501029-19-00
Hospices Civils De LyonAsthma
Start: 2022-12-13End: 2025-03-27Target: 130Updated: 2024-01-15
THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+)
CompletedCTIS2023-507304-32-00
Fundacio Privada Mon Clinic BarcelonaChronic Obstructive Pulmonary Disease
Start: 2024-02-09End: 2025-01-23Target: 1028Updated: 2024-04-04
Phase IV, single-center, double blind, randomized, crossover, placebo-controlled study, to investigate the effect of dual bronchodilation with umeclidinium/vilanterol on patients with COPD, hyperinflation and heart failure
Not yet recruitingCTIS2024-519513-61-00
Hospital General Universitario Gregorio MaranonChronic obstructive pulmonary diseases with Heart Failure with eyection ventricular ejection fraction between 35-50%
Target: 60Updated: 2024-11-20